Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.59 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.52 |
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3005360 | 0.85 | UBE2T (0.63) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7435843 | 0.82 | UBE2T (0.56) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL17788588 | 0.82 | UBE2T (0.56) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL226465 | 0.82 | UBE2T (0.70) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL23970354 | 0.81 | UBE2T (0.59) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL15979343 | 0.81 | HPGD (0.54) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| Bromide SCHEMBL7601035 | 0.80 | UBE2T (0.68) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7265353 | 0.80 | SMN1; SMN2 (0.57) | UBE2TASIC3SMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL29838366 | 0.79 | HPGD (0.63) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL322456 | 0.79 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| WO-2023222680-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2023-11-23 | — | — | WO | disclosed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| CN-108699035-B | Novel compounds | 特殊治疗有限公司 | 2021-10-15 | — | — | CN | disclosed |
| US-11053260-B2 | Tri-cycle compound and applications thereof | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| EP-3587420-B1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-03-31 | — | — | EP | disclosed |
| CN-109020916-B | Substituted benzothiazole C2 alkylated derivative and application thereof | 浙江工业大学 | 2021-02-09 | — | — | CN | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20040122040-A1 | Bicyclic guanidine derivatives and therapeutic uses thereof | MERCK PATENT GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1370542-A1 | BICYCLIC GUANIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF | MERCK PATENT GmbH (DE) | 2003-12-17 | — | — | EP | disclosed |
| EP-0767792-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2002076963-A1 | BICYCLIC GUANIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2002-10-03 | — | — | WO | disclosed |
| US-5977101-A | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| CN-1156995-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1997-08-13 | — | — | CN | disclosed |
| EP-0767792-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | UBE2T 882/4885ASIC3 4263/4885SMN1; SMN2 4123/4885 |
| US-20240016941-A1 | COMBINATION THERAPY | CFTR, ABCB11, SLC26A4 | UBE2T 2566/4885ASIC3 420/4885SMN1; SMN2 3442/4885 |
| US-20040122040-A1 | Bicyclic guanidine derivatives and therapeutic uses thereof | GPR119, GCKR, GUCY1A1 | UBE2T 4749/4885ASIC3 3065/4885SMN1; SMN2 506/4885 |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | UBE2T 2761/4885ASIC3 3168/4885SMN1; SMN2 699/4885 |
| US-11053260-B2 | Tri-cycle compound and applications thereof | SLC10A1, NR1H4, HAVCR2 | UBE2T 1507/4885ASIC3 3804/4885SMN1; SMN2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.